Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery

• Status: Unknown status
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To-date there have been only very few studies to examine the effect of cataract surgery to patients with wet age-related macular degeneration. The evidence on the effects of cataract surgery in such patients suggests improvement of their visual function and quality of life, but at the same time a subclinical susceptibility to macular edema and exacerbation of the choroidal neovascularization. Therefore it is highly important to identify the optimum treatment regime, pursuing the best anatomical and functional postoperative results.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ophthalmica Eye Institute
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Active choroidal neovascularization (at least 1 intravitreal injection in the past 12 months) associated with AMD and involving the foveal center

• BCVA of 1.0 (LogMAR) or better

• Duration of wet AMD less than 3 years

Exclusion Criteria:

• Coexisting ocular pathology potentially affecting visual acuity and/or status of the macula including diabetic retinopathy, advanced glaucoma, retinal vein occlusion, retinal detachment

• Newly diagnosed patients with wet AMD who are on anti-VEGF treatment for less than 6 months